CN116063576A - Fshr-dtt重组去势疫苗及其制备方法和应用 - Google Patents
Fshr-dtt重组去势疫苗及其制备方法和应用 Download PDFInfo
- Publication number
- CN116063576A CN116063576A CN202211434748.3A CN202211434748A CN116063576A CN 116063576 A CN116063576 A CN 116063576A CN 202211434748 A CN202211434748 A CN 202211434748A CN 116063576 A CN116063576 A CN 116063576A
- Authority
- CN
- China
- Prior art keywords
- fshr
- dtt
- recombinant
- sequence
- castration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 15
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 12
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 12
- 102000016607 Diphtheria Toxin Human genes 0.000 claims abstract description 10
- 108010053187 Diphtheria Toxin Proteins 0.000 claims abstract description 10
- 102100027627 Follicle-stimulating hormone receptor Human genes 0.000 claims abstract 9
- 101000862396 Homo sapiens Follicle-stimulating hormone receptor Proteins 0.000 claims abstract 9
- 239000013612 plasmid Substances 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 241000282898 Sus scrofa Species 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 claims description 2
- 101100120660 Sus scrofa FSHR gene Proteins 0.000 claims description 2
- 230000035558 fertility Effects 0.000 claims description 2
- 238000005457 optimization Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 230000005847 immunogenicity Effects 0.000 abstract description 9
- 108091007433 antigens Proteins 0.000 abstract description 8
- 102000036639 antigens Human genes 0.000 abstract description 8
- 239000000427 antigen Substances 0.000 abstract description 7
- 230000001900 immune effect Effects 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 230000006798 recombination Effects 0.000 abstract description 3
- 238000005215 recombination Methods 0.000 abstract description 3
- 108010060374 FSH Receptors Proteins 0.000 description 24
- 102000018343 Follicle stimulating hormone receptors Human genes 0.000 description 24
- 238000012360 testing method Methods 0.000 description 20
- 210000001550 testis Anatomy 0.000 description 16
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000002863 seminiferous tubule Anatomy 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011537 Coomassie blue staining Methods 0.000 description 2
- 101150105763 FSHR gene Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000023508 male gonad development Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000920 spermatogeneic effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229940124462 contraceptive vaccine Drugs 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108010067479 inhibin B Proteins 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940051173 recombinant immunotoxin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明属于分子疫苗学技术领域,公开了一种FSHR‑DTT重组去势疫苗,其含有如序列表Seq_1所示的动物FSHR序列以及如序列表Seq_2所示的白喉毒素跨膜区域氨基酸序列;其氨基酸序列,如序列表Seq_3所示。同时,公开了一种FSHR‑DTT重组去势疫苗的制备方法和应用。本发明中采取FSHR和DTT蛋白重组的方式,生产的FSHR‑DTT重组去势疫苗,抗原免疫原性高,免疫效果好,稳定性高;同时使用的是重组FSHR‑DTT蛋白,减少了多肽合成制剂成本,使用更加便利;采用FSHR和DTT重组蛋白表达方式,表达量高,免疫原性好,疫苗制剂简单,有利于产业化应用。
Description
技术领域
本发明涉及分子疫苗学技术领域,具体为FSHR-DTT重组去势疫苗及其制备方法和应用。
背景技术
传统去势术较为常用的方式为手术阉割法,这种方法对场地、环境、操作等均有较高的要求,与此同时手术会产生副作用,如感染率高导致一定的死亡,且对家畜年出栏量巨大的中国而言带来一定的困难,另外手术成本较高,也不利于动物福利,这种沿袭千年的手术阉割正受到规模化、标准化畜牧生产需求的挑战,研究表明,免疫去势术具有方便高效、可逆、安全等优点,因此,免疫去势技术最有望成为传统去势术的替代者。
FSH(follicle-stimulating hormone)主要提高雌性动物卵泡壁细胞的摄氧能力,促进有腔卵泡发育,促进雄性动物睾丸支持细胞增殖、抑制素B的分泌及维持精子发生。完整的FSH不是推荐的疫苗靶点。将完整的hFSHβ亚基作为抗原对大鼠进行免疫,虽然能够产生明显的抗体滴度,但是避孕效果不佳,并且产生的抗体会针对相关糖蛋白激素保守区域,这样可能会干扰如LH等激素的功能。
FSHR(follicle-stimulating hormone receptor)受体蛋白可以代替FSH在避孕疫苗开发中的位置。FSHR疫苗是通过刺激机体产生相应抗体与细胞表面的FSHR结合,从而抑制其与FSH结合,间接抑制FSH发挥生物学功能,达到去势的目的。
目前,传统的的FSHR去势疫苗,抗原免疫原性不高,生产表达量低,制备困难,免疫效果不好,生产成本高,不利于产业化应用。
发明内容
本发明的目的在于:提供一种FSHR-DTT重组去势疫苗及其制备方法和应用,以解决以上缺陷。
为了实现上述目的,本发明提供如下技术方案:
一种FSHR-DTT重组去势疫苗,所述FSHR-DTT重组去势疫苗的氨基酸序列,含有如序列表Seq_1所示的动物FSHR序列。
优选地,所述动物FSHR序列,为家猪的FSHR序列,或宠物猫的FSHR序列,或啮齿类宠物的FSHR序列。
优选地,所述FSHR-DTT重组去势疫苗的氨基酸序列,含有如序列表Seq_2所示的白喉毒素跨膜区域氨基酸序列。
优选地,所述FSHR-DTT重组去势疫苗的氨基酸序列,如序列表Seq_3所示。
优选地,所述FSHR-DTT重组去势疫苗,是由含有如序列表Seq_4所示的工程菌BL21(DE3)-pET28a-FSHR-DTT表达出的重组蛋白。
优选地,一种FSHR-DTT重组去势疫苗的制备方法,包括如下步骤:
S1.根据如序列表Seq_1所示的动物FSHR序列和如序列表SEQ_2所示的白喉毒素跨膜区域氨基酸序列,设计出包含选定的FSHR重组DTT序列;
S2.采用密码子优化系统设计合成带Nde I和Xho I酶切位点的如序列表SEQ_4所示DNA序列,经Nde I和Xho I双酶切后DNA产物与同样酶切的载体pET28a连接;
S3.随后将连接液转入大肠杆菌DH5α,筛选得到质粒pET28a-FSHR-DTT,通过将质粒FSHR-DTT转入大肠杆菌BL21(DE3)菌株,得到工程菌BL21(DE3)-pET28a-FSHR-DTT,最终表达出含序列表Seq_3所示的氨基酸的重组蛋白。
优选地,所述FSHR-DTT重组去势疫苗应用于哺乳动物生育能力控制。
本发明的有益效果在于:
本发明中,采取FSHR和DTT蛋白重组的方式,生产的FSHR-DTT重组去势疫苗,提高了抗原免疫原性,提高了抗原的免疫效果,避免了多肽不稳定的效果;同时本发明使用的是重组FSHR-DTT蛋白,减少了多肽合成制剂成本,使用更加便利。而且本发明采用FSHR和DTT重组蛋白表达方式,作为制备动物去势疫苗的一种方法,其表达量高,免疫原性好、疫苗制剂简单,能够有效的提高其免疫效果,使去势技术更优化,有利于产业化应用。
附图说明
图1为本发明实施例中合成重组蛋白FSHR-DTT的DNA的结构示意图;
图2为本发明实施例中的pET28a-FSHR-DTT质粒图谱图;
图3为本发明实施例中重组蛋白FSHR-DTT纯化后SDS-PAGE电泳胶考马斯亮蓝染色图;
图4为本发明实施例中的重组蛋白FSHR-DTT纯化后蛋白免疫印迹(Western BLot)分析图;
图5为本发明实施例中的试验组与对照组的动物睾丸图;
图6为本发明实施例中的试验动物免疫后睾丸切片图;
图7为本发明实施例中的实验动物免疫后对试验组与对照组睾丸发育的影响图。
具体实施方式
在本发明中所使用的术语,除非有另外说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体的制备实施例和应用实施例,并参照数据进一步详细地描述本发明。应理解,这些实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
在以下的实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。所用到的引物,均在首次出现时标明,其后所用相同引物,均以首次标明的内容相同。
实施例1:
一、FSHR-DTT重组去势疫苗表达载体的构建
质粒pET28a-FSHR-DTT的构建:
白喉毒素(Diphtheria toxin,DT)来自β棒状噬菌体溶源化白喉杆菌,常用于重组免疫毒素的细菌毒素,由535个氨基酸组成,分子量大约为58KDa。毒素可以分为22KD的A片段和38KD的B片段。A片段位于毒素氨基末端,它进入细胞内会导致细胞死亡。B片段由酶活性区、跨膜区和受体结合区组成,不包含致毒因素。白喉毒素跨膜区(DTT domain)氨基酸序列在202-378,由9个α螺旋构成,包含两个主要T辅助表位,DTT271-290和DTT321-370。使用DTT作为疫苗制作的载体蛋白,可以增强目的蛋白的免疫原性,加强疫苗的效果。
本发明中,首先,根据家猪FSHR序列(包括但不限于家猪序列,也可以为宠物猫的FSHR序列,或啮齿类等宠物的FSHR序列,例如荷兰猪、小鼠等)和白喉毒素跨膜区域氨基酸序列,设计出包含选定的FSHR重组DTT序列。
其中,家猪FSHR序列,如序列表Seq_1所示,具体如下:
Mskvteippdlpggsihncafngtqggggsskvteippdlpggsihncafngtqggggsskvteippdlpggsihncafngtqggggs。
其中,白喉毒素跨膜区域氨基酸序列,如序列表Seq_2所示,具体如下:
Inldwdvirdktktkieslkehgpiknkmsespnktvseekakqyleefhqtalehpelselkt vtgtnpvfaganyaawavnvaqvidsetadnlekttaalsilpgigsvmgiadgavhhnteeivaqsi alsslmvaqaiplvgelvdigfaaynfvesiinlfqvvhnsynrp。
合成FSHR-DTT的DNA序列,其5’端和3’端分别加Nde I和Xho I酶切位点,FSHR和DTT之间加BamH I酶切位点,其结构示意图如图1所示。
合成FSHR-DTT的DNA序列,如序列表Seq_4所示,具体如下:
catatgATGAGCAAAGTGACCGAAATTCCGCCGGATCTGCCGGGTGGTTCTATTCACAACTGCGCATTCAACGGTACCCAGGGTGGTGGTGGTTCTAGCAAAGTGACCGAAATTCCGCCGGATCTGCCGGGTGGTTCTATTCACAACTGCGCATTCAACGGTACCCAGGGTGGTGGTGGTTCTAGCAAAGTGACCGAAATTCCGCCGGATCTGCCGGGTGGTTCTATTCACAACTGCGCATTCAACGGTACCCAGGGTGGTGGTGGTTCTggatcCataaatcttgattgggatgtcataagggataaaactaagacaaagatagagtctttgaaagagcatggccctatcaaaaataaaatgagcgaaagtcccaataaaacagtatctgaggaaaaagctaaacaatacctagaagaatttcatcaaacggcattagagcatcctgaattgtcagaacttaaaaccgttactgggaccaatcctgtattcgctggggctaactatgcggcgtgggcagtaaacgttgcgcaagttatcgatagcgaaacagctgataatttggaaaagacaactgctgctctttcgatacttcctggtatcggtagcgtaatgggcattgcagacggtgccgttcaccacaatacagaagagatagtggcacaatcaatagctttatcatctttaatggttgctcaagctattccattggtaggagagctagttgatattggtttcgctgcatataattttgtagagagtattatcaatttatttcaagtagttcataattcgtataatcgtcccCTCGAg。
将合成的FSHR-DTT的DNA片段和pET28a质粒分别用Nde I和Xho I进行双酶切,双酶切体系分别为FSHR-DTT DNA片段(100ng/μL)或pET28a(100ng/μL)40μL,其余体系均为10×CutSmart Buffer10μL,Nde I和Xho I各1μL以及灭菌超纯水48μL。37℃酶切10h,核酸电泳分离目的片段,将目的条带切下来,用DNA凝胶回收试剂盒进行纯化。将Nde I和Xho I双酶切的FSHR-DTT片段和pET28a载体按照摩尔比5:1使用T4连接酶4℃连接过夜,连接混合液转化大肠杆菌DH5α后在含有50μg/mL卡那霉素(K+)的LB固体培养基上培养过夜,挑取几个单克隆测序,选择序列正确的菌提取质粒,即为质粒pET28a-FSHR-DTT,其质粒图谱如图2所示。
质粒提取及双酶切电泳回收均使用“北京艾德莱生命科技有限公司”的相应试剂盒。质粒、DNA连接液转化进入大肠杆菌皆用感受态细胞方法;所有限制性内切酶和连接酶皆购自于“北京纽英伦生物技术有限公司”。
二、FSHR-DTT重组去势疫苗蛋白的诱导表达和纯化
1.菌的制备:将上述的质粒pET28a-FSHR-DTT用常规方法转化大肠杆菌BL21(DE3),在含有K+(50μg/mL)的LB固体培养基上培养12-15h,挑取一个转化子于含有K+(50μg/mL)的LB液体培养基(10mL)中37℃,200rpm,16h;取1mL,16h培养后的菌液,加入100mL新鲜的含有K+(50μg/mL)的LB液体培养基中,于37℃下转速200rpm摇动培养至3h,使OD600为1.0时,加入终浓度为1.0mM的IPTG,20℃继续以转速200rpm摇动培养12h,以4000g,4℃离心45min,收集菌沉淀。
其中,质粒pET28a-FSHR-DTT转化大肠杆菌BL21(DE3)菌株后得到的工程菌即为BL21(DE3)-pET28a-FSHR-DTT。BL21(DE3)-pET28a-FSHR-DTT工程菌目前已经进行保藏,其由安徽农业大学提供,保藏单位:中国微生物菌种保藏管理委员会普通微生物中心,保藏号CGMCC No.25690。
2.破菌:取100mL菌沉淀加入8mL(8%)非变性裂解液进行重悬,其中非变性裂解液为终浓度的50mMTris>500mMNaC1,pH7.5;将重悬的菌体于-20℃冻存或直接用于超声,超声时可加入蛋白酶抑制剂PMSF(按1:100-1:1000稀释,工作浓度为17-174μg/mL);超声功率为200W,超声4s,间歇2s,超声20min;超声结束后,菌液在4℃下,10000g,离心30min,弃沉淀,取上清,将上清进行镍柱纯化后经SDS-PAGE电泳检测(80V电压下电泳30min,随后120V电压下电泳60min),考马斯亮蓝染色。
图3为本发明实施例中重组蛋白FSHR-DTT纯化后SDS-PAGE电泳胶考马斯亮蓝染色图。其中E1-E4为纯化后FSHR-DTT(29.0KDA)的蛋白条带,如图3所示可见,pET28a-FSHR-DTT大肠杆菌(BL21)在经过HIS标签的镍柱纯化后,可以得到高浓度的FSHR-DTT蛋白。
测定纯化后的蛋白的分子量大小,将纯化的蛋白经WB分析。图4为重组蛋白FSHR-DTT纯化后蛋白免疫印迹(Western BLot)分析图,其中,条带1表示Mark条带,条带2-3表示FSHR-DTT(29.0KDa)与FSHR抗体反应条带。如图4所示可见,研制出的FSHR-DTT蛋白与FSHR抗体具有良好的反应原性。
由此可见,证实纯化的蛋白为抗原蛋白FSHR-DTT,其氨基酸序列(带有BamH I酶切位点)如序列表Seq_3所示,具体如下:
Mskvteippdlpggsihncafngtqggggsskvteippdlpggsihncafngtqggggsskvteippdlpggsihncafngtqggggsgsinldwdvirdktktkieslkehgpiknkmsespnktvs eekakqyleefhqtalehpelselktvtgtnpvfaganyaawavnvaqvidsetadnlekttaalsilpgigsvmgiadgavhhnteeivaqsialsslmvaqaiplvgelvdigfaaynfvesiinlfqvvhnsynrp。
三、FSHR-DTT重组去势疫苗的应用
1.对比试验。选取幼年雄性大鼠20只,对照组和试验组各10只,20日龄初次免疫,其中试验组采用的是本发明制备的FSHR-DTT重组去势疫苗,而对照组采用的是相同剂量的DTT蛋白和佐剂。间隔2周加强免疫,共免疫2次,首免后第16周处死。取睾丸样品制备切片,苏木精-伊红染色观察组织学结构。
2.FSHR-DTT疫苗的免疫去势结果评估:
图5为上述试验组与对照组的动物睾丸图。如图5所示,肉眼可见试验免疫组(左)的睾丸大小明显小于对照组(右)的睾丸大小,可见FSHR-DTT抑制了大鼠睾丸的发育,最终发生萎缩,说明研制出的FSHR-DTT具有很强的免疫原性。
图6为本发明实施例中的试验动物免疫后睾丸切片图。其中,A.对照组DTT组(100×);B.FSHR组(100×);a.对照组DTT组(400×);b.FSHR组(400×)。S指生精小管;方框:精子;短箭:精原细胞;三角形:初级精母细胞。如图6所示,试验组大鼠的睾丸组织切片可以观察到试验组睾丸曲细精管内部精原细胞减少,管腔内空隙增大,曲细精管之间的空隙增大。对照组大鼠的睾丸生精小管结构正常,生精小管中有正常的精原细胞、精母细胞、精子细胞及精子,并且层次分明,有大量精子产生。
图7为本发明实施例中的实验动物免疫后对试验组与对照组睾丸发育的影响图;其中,FSHR组即为采用FSHR-DTT重组去势疫苗的试验组,A.睾丸指数;B.睾丸纵径;C.睾丸横径;通过SPSS软件分析,*代表俩组数据之间存在显著差异,用(p<0.05)表示。如图7所示,可以看出在首次免疫16w后,试验组公鼠的睾丸指数显著低于对照组组(p<0.05),试验组睾丸纵径显著小于对照组(p<0.05),试验组睾丸横径显著小于对照组(p<0.05)。。由此可说明FSHR-DTT重组去势疫苗可以有效抑制大鼠睾丸的发育。
本发明中,采取FSHR和DTT蛋白重组的方式,生产的FSHR-DTT重组去势疫苗,提高了抗原免疫原性,提高了抗原的免疫效果,避免了多肽不稳定的效果;同时本发明使用的是重组FSHR-DTT蛋白,减少了多肽合成制剂成本,使用更加便利。而且本发明采用FSHR和DTT重组蛋白表达方式,作为制备动物去势疫苗的一种方法,其表达量高,免疫原性好、疫苗制剂简单,能够有效的提高其免疫效果,使去势技术更优化,有利于产业化应用。
上述是对发明进行了示例性描述,显然本发明具体实现并不受上述方式的限制,只要采用了本发明的方法构思和技术方案进行的这种非实质改进,或未经改进将发明的构思和技术方案直接应用于其他场合的,均在本发明的保护范围之内。
Claims (7)
1.一种FSHR-DTT重组去势疫苗,其特征在于,所述FSHR-DTT重组去势疫苗的氨基酸序列,含有如序列表Seq_1所示的动物FSHR序列。
2.根据权利要求1所述的FSHR-DTT重组去势疫苗,其特征在于,所述动物FSHR序列,为家猪的FSHR序列,或宠物猫的FSHR序列,或啮齿类宠物的FSHR序列。
3.根据权利要求1所述的FSHR-DTT重组去势疫苗,其特征在于,所述FSHR-DTT重组去势疫苗的氨基酸序列,还含有如序列表Seq_2所示的白喉毒素跨膜区域氨基酸序列。
4.根据权利要求1所述的FSHR-DTT重组去势疫苗,其特征在于,所述FSHR-DTT重组去势疫苗的氨基酸序列,如序列表Seq_3所示。
5.根据权利要求4所述的FSHR-DTT重组去势疫苗,其特征在于,所述FSHR-DTT重组去势疫苗,是由含有如序列表Seq_4所示的工程菌BL21(DE3)-pET28a-FSHR-DTT表达出的重组蛋白。
6.一种如权利要求1-4所述的FSHR-DTT重组去势疫苗的制备方法,其特征在于,包括如下步骤:
S1.根据如序列表Seq_1所示的动物FSHR序列和如序列表Seq_2所示的白喉毒素跨膜区域氨基酸序列,设计出包含选定的FSHR重组DTT序列;
S2.采用密码子优化系统设计合成带Nde I和Xho I酶切位点的如序列表Seq_4所示DNA序列,经Nde I和Xho I双酶切后DNA产物与同样酶切的载体pET28a连接;
S3.随后将连接液转入大肠杆菌DH5α,筛选得到质粒pET28a-FSHR-DTT,通过将质粒FSHR-DTT转入大肠杆菌BL21(DE3)菌株,得到工程菌BL21(DE3)-pET28a-FSHR-DTT,最终表达出含序列表Seq_3所示的氨基酸的重组蛋白。
7.一种如权利要求1-4所述的FSHR-DTT重组去势疫苗的应用,其特征在于,所述FSHR-DTT重组去势疫苗应用于哺乳动物生育能力控制。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211434748.3A CN116063576A (zh) | 2022-11-16 | 2022-11-16 | Fshr-dtt重组去势疫苗及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211434748.3A CN116063576A (zh) | 2022-11-16 | 2022-11-16 | Fshr-dtt重组去势疫苗及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116063576A true CN116063576A (zh) | 2023-05-05 |
Family
ID=86175863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211434748.3A Pending CN116063576A (zh) | 2022-11-16 | 2022-11-16 | Fshr-dtt重组去势疫苗及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116063576A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986007383A1 (en) * | 1985-06-04 | 1986-12-18 | Biotechnology Research Partners, Ltd. | Autoantigen vaccines |
EP1579873A1 (en) * | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
CN105085684A (zh) * | 2014-05-14 | 2015-11-25 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
CN109265564A (zh) * | 2018-09-27 | 2019-01-25 | 广东药科大学 | 一种鼠抗cd3重组免疫毒素及其制备方法和应用 |
CN114605542A (zh) * | 2020-12-04 | 2022-06-10 | 康威(广州)生物科技有限公司 | 抗fshr抗体及其抗体-药物偶联物的制备和应用 |
-
2022
- 2022-11-16 CN CN202211434748.3A patent/CN116063576A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986007383A1 (en) * | 1985-06-04 | 1986-12-18 | Biotechnology Research Partners, Ltd. | Autoantigen vaccines |
EP1579873A1 (en) * | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
CN105085684A (zh) * | 2014-05-14 | 2015-11-25 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
CN109265564A (zh) * | 2018-09-27 | 2019-01-25 | 广东药科大学 | 一种鼠抗cd3重组免疫毒素及其制备方法和应用 |
CN114605542A (zh) * | 2020-12-04 | 2022-06-10 | 康威(广州)生物科技有限公司 | 抗fshr抗体及其抗体-药物偶联物的制备和应用 |
Non-Patent Citations (1)
Title |
---|
"中国畜牧兽医第38卷总目次", 中国畜牧兽医, no. 12, 20 December 2011 (2011-12-20) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH04506005A (ja) | 破傷風トキシンフラグメントcの発現 | |
WO1999042472A1 (en) | Heat shock fusion-based vaccine system | |
CN105925597B (zh) | 一种pedv s基因主要抗原表位串联的重组基因及其制备方法和应用 | |
Lightowlers et al. | Host‐protective fragments and antibody binding epitopes of the Taenia ovis 45W recombinant antigen | |
CN110845582B (zh) | 一种猫细小病毒重组蛋白及其单克隆抗体的制备 | |
CN113121704B (zh) | 基于纳米颗粒的冠状病毒疫苗 | |
CN111363048B (zh) | 一种具有穿膜活性的可溶性重组苦荞金属硫蛋白FtMT及其制备方法 | |
CN116162173A (zh) | 一种GnRH6-CRM197重组蛋白去势疫苗及制备方法 | |
CN108904788B (zh) | GnRH-防御素重组去势疫苗及其制备 | |
CN116063576A (zh) | Fshr-dtt重组去势疫苗及其制备方法和应用 | |
CN111569056A (zh) | 一种猪轮状病毒疫苗、制备该疫苗的抗原及其编码序列 | |
CN116617377A (zh) | GnRH8-DTT重组去势疫苗及其制备方法和应用 | |
JPS62272989A (ja) | 融合タンパク質、抗体およびこれらの製造方法 | |
CN113087788B (zh) | 一种特异性识别小麦内源自噬相关蛋白8多克隆抗体的制备方法 | |
CN111018966B (zh) | Hemibarbus maculatus胰岛素样生长因子3、其蛋白、其抗体及应用 | |
CN106929512A (zh) | St2抗原的制备及其专用编码dna分子 | |
CN115746146B (zh) | 一种GnRH重组蛋白抗原、哺乳动物去势重组蛋白疫苗及制备方法 | |
CN116987201B (zh) | 调控哺乳动物生殖能力的多聚重组蛋白、制备方法和应用 | |
CN105906716A (zh) | 埃可病毒9型vp1蛋白特异性抗原表位及其融合蛋白的制备、应用 | |
FANG et al. | Immunization of male mice with a new recombinant GnRH fusion protein reduces the testicular function | |
CN113683707B (zh) | 一种抗原融合蛋白及其编码基因和应用 | |
CN117003898B (zh) | 一种lhrh4-crm197-lf多聚重组蛋白及其制备方法和应用 | |
CN114196691B (zh) | 一种制备防治牛、羊棘球蚴病多表位重组疫苗的基因、蛋白质、疫苗和应用 | |
CN109942718B (zh) | 一种无毒性破伤风毒素和产气荚膜梭菌β毒素重组融合蛋白 | |
EP4289960A1 (en) | Preparation method for modified toxin polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |